The understanding of the mechanisms and the further identification of LRP1 partners may open up new ways to treat metabolic diseases, such as lipid metabolism, atherosclerosis, inflammation, Alzheimer's disease and obesity. This evidence concerns the gene LRP1 and obesity due to melanocortin 4 receptor deficiency.